

Scientific Session NRG Oncology Research Review Agenda

Advancing Research. Improving Lives.™

Date: Friday, February 10, 2017
Start and End Time: 8:00 am – 10:00 am
Co-Chairs: Deborah Bruner, PhD; Fred Stehman, MD; Elizabeth Gore, MD
Moderator: Thomas B Julian, MD

8:00 – 8:05 am	Welcome	Thomas B Julian, MD
8:05 – 8:15 am	A mutation and prognostic biomarker study in grade II and III gliomas utilizing a combined cohort of NRG Oncology RTOG 9802 and 9813.	Erica Bell, PhD
8:15-8:20 am	Questions	
8:20 – 8:30 am	Initial report of NRG Oncology RTOG 0232: A phase 3 study comparing combined external beam radiation and transperineal interstitial permanent brachytherapy with brachytherapy lone for selected patients with intermediate-risk prostatic carcinoma	Bradley Prestidge, MD
8:30-8:35 am	Questions	
8:35 – 8:45 am	NRG Oncology RTOG 0415, Phase 3 noninferiority study comparing 2 fractionation schedules in patients with low-risk prostate cancer: Prostate-specific quality of life results.	Deborah Bruner, RN, PhD
8:45-8:50 am	Questions	
8:50 – 9:00 am	Final results of NRG Oncology RTOG 0246: An organ preserving selective resection strategy in esophageal cancer patients treated with definitive chemoradiation.	Steven Swisher, MD
9:00 – 9:05 am	Questions	
9:05 – 9:15 am	A phase III clinical trial of bevacizumab with IV versus IP chemotherapy in ovarian, fallopian tube and primary peritoneal carcinoma: NRG Oncology GOG 0252	Joan Walker, MD
9:15 – 9:20 am	Questions	
9:20 – 9:30 am	A phase III trial evaluating pCR in patients with HR+, HER2-positive breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP) +/- estrogen deprivation: NRG Oncology NSABP B-52.	Priya Rastogi, MD
9:30 – 9:35 am	Questions	
9:35 – 9:45 am	A randomized, double-blinded, placebo-controlled clinical trial to evaluate extended adjuvant endocrine therapy (5 years of letrozole) in postmenopausal women with hormone-receptor positive breast cancer who have completed previous adjuvant endocrine therapy: Initial results of NRG Oncology NSABP B-42.	Terry Mamounas, MD
9:45 -9:50 am	Questions	

Learning Objectives:

Following this activity, participants will be better able to:

1. Discuss the prognostic value of IDH1/2 mutations and CIC to predict overall survival in patients with grade II glioma.
2. Describe the findings of the recent initial analysis of a phase 3 trial to determine if combined external beam therapy and transperineal interstitial permanent brachytherapy results in better progression-free survival at five years compared to brachytherapy alone, among selected intermediate-risk prostatic carcinoma patients.
3. Identify the differences in health related quality of life (HRQoL) between hypofractionated and conventional schedule radiation therapy in men with low-risk prostate cancer.

4. Discuss the impact of selective surgical resection for esophageal cancer patients treated with definitive chemoradiation.
5. Describe the impact on progression-free survival for two intraperitoneal chemotherapy regimens as compared to standard intravenous chemotherapy for first-line treatment of surgically resected stage II/II ovarian, peritoneal or fallopian tube cancer.
6. Discuss the role of adding estrogen deprivation to neoadjuvant chemotherapy for women with HER2+ breast cancer.
7. Describe the findings of an analysis of a phase 3 trial examining the role of extending adjuvant endocrine therapy with letrozole for five years in postmenopausal women with stage I-III hormone-receptor breast cancer who had received five years of treatment with either tamoxifen or an aromatase inhibitor